Quick Answer
Allogene Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $51.69 million for the year ending 2025.
- Allogene Therapeutics, Inc. showed a decrease of -31.3% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Allogene Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2018 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2018: $83.14 million | Q1 2019: $92.75 million | Q2 2019: $112.58 million | Q3 2019: $160.99 million | Q1 2020: $135.90 million | Q2 2020: $280.38 million | Q3 2020: $158.14 million | Q1 2021: $236.87 million | Q2 2021: $223.50 million | Q3 2021: $190.02 million | Q1 2024: $51.04 million | Q2 2024: $170.67 million | Q3 2024: $51.24 million | Q1 2025: $42.46 million | Q2 2025: $52.33 million | Q3 2025: $37.82 million.
- Over the full 14 years of available data (2018 to 2025), Allogene Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has declined by 44.1%.
- Historical annual values: Fiscal year 2025: $51.69 million | Fiscal year 2024: $75.22 million | Fiscal year 2023: $83.16 million | Fiscal year 2023: $69.25 million | Fiscal year 2023: $154.76 million | Fiscal year 2023: $109.93 million | Fiscal year 2022: $61.90 million | Fiscal year 2022: $74.36 million | Fiscal year 2022: $96.04 million | Fiscal year 2022: $84.51 million | Fiscal year 2021: $173.31 million | Fiscal year 2020: $183.35 million | Fiscal year 2019: $175.13 million | Fiscal year 2018: $92.43 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: